Gain-of-function mutations in LRRK2, which encodes the leucine-rich repeat kinase 2
(LRRK2), are the most common genetic cause of late-onset Parkinson's disease. LRRK2 is …

LRRK2 is one of the most promising drug targets for Parkinson's disease. Though type I
kinase inhibitors of LRRK2 are under clinical trials, alternative strategies like type II inhibitors …

Point mutations in leucine-rich repeat kinase 2 (LRRK2) which cause Parkinson's disease
increase its kinase activity, and a subset of Rab GTPases have been identified as …

Mutations of the human leucine-rich repeat kinase 2 (LRRK2) have been associated with
both, idiopathic and familial Parkinson's disease (PD). Most of these pathogenic mutations …

Although the αC-β4 loop is a stable feature of all protein kinases, the importance of this motif
as a conserved element of secondary structure, as well as its links to the hydrophobic …

The human leucine-rich repeat kinases (LRRKs), LRRK1 and LRRK2 are large and
unusually complex multi-domain kinases, which regulate fundamental cellular processes …

LRR-kinase 2 (LRRK2) is a multi-domain protein with three catalytically inert N-terminal
domains (NtDs) and four C-terminal domains, including a kinase and a GTPase domain …

Roco proteins entered the limelight after mutations in human LRRK2 were identified as a
major cause of familial Parkinson's disease. LRRK2 is a large and complex protein …

Leucine-rich repeat kinase 2 (LRRK2) is a large, multi-domain protein which is associated
with Parkinson's disease. Although high-resolution structures of LRRK2 are available, little is …

Esophageal squamous cell carcinoma (ESCC) is a clinically common heterogeneous
malignant tumor of the digestive system and also one of the diseases with a high incidence …